Contact Us
Drug Search Results
More Filters [+]

Pyrimethamine

Alternative Names: pyrimethamine, daraprim, pyrimethamin, maloprim, fansidar
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Pyrimethamine is an antiparasitic prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Toxoplasma gondiiinfection (toxoplasmosis). Pyrimethamine is usually used together with a sulfonamide (sulfa medicine) to treat toxoplasmosis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimethamine)

Mechanisms of Action: DHFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | India | Indonesia | Ireland | Italy | Jordan | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | United Kingdom | United States | Uruguay | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pyrimethamine

Countries in Clinic: Jordan

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Bladder Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Prostate Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Triple Negative Breast Cancer

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SUPY-T005

P1

Not yet recruiting

Healthy Volunteers

2024-08-01

2017-005057-36

P2

Active, not recruiting

Small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Cancer|Ovarian Cancer|Melanoma|Renal Cell Carcinoma|Esophageal Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Bladder Cancer|Head and Neck Cancer|Prostate Cancer

2018-11-23

Recent News Events

Date

Type

Title

10/29/2024

News Article

 Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

09/24/2024

News Article

 SierraConstellation Partners Wins Multiple Turnaround Atlas Awards from The Global M&A Network

04/26/2024

News Article

 Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa

12/14/2023

News Article

 Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions